1. Home
  2. BHE vs MESO Comparison

BHE vs MESO Comparison

Compare BHE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHE
  • MESO
  • Stock Information
  • Founded
  • BHE 1979
  • MESO 2004
  • Country
  • BHE United States
  • MESO Australia
  • Employees
  • BHE N/A
  • MESO N/A
  • Industry
  • BHE Electrical Products
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BHE Technology
  • MESO Health Care
  • Exchange
  • BHE Nasdaq
  • MESO Nasdaq
  • Market Cap
  • BHE 1.4B
  • MESO 1.3B
  • IPO Year
  • BHE 1990
  • MESO N/A
  • Fundamental
  • Price
  • BHE $43.05
  • MESO $15.60
  • Analyst Decision
  • BHE Strong Buy
  • MESO Buy
  • Analyst Count
  • BHE 2
  • MESO 2
  • Target Price
  • BHE $46.50
  • MESO $24.00
  • AVG Volume (30 Days)
  • BHE 270.6K
  • MESO 213.4K
  • Earning Date
  • BHE 11-04-2025
  • MESO 08-28-2025
  • Dividend Yield
  • BHE 1.55%
  • MESO N/A
  • EPS Growth
  • BHE N/A
  • MESO N/A
  • EPS
  • BHE 1.05
  • MESO N/A
  • Revenue
  • BHE $2,588,733,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • BHE $0.03
  • MESO $288.50
  • Revenue Next Year
  • BHE $5.83
  • MESO $167.17
  • P/E Ratio
  • BHE $41.09
  • MESO N/A
  • Revenue Growth
  • BHE N/A
  • MESO 191.39
  • 52 Week Low
  • BHE $30.73
  • MESO $8.34
  • 52 Week High
  • BHE $52.57
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • BHE 59.71
  • MESO 39.64
  • Support Level
  • BHE $42.77
  • MESO $16.10
  • Resistance Level
  • BHE $44.29
  • MESO $16.91
  • Average True Range (ATR)
  • BHE 1.21
  • MESO 0.50
  • MACD
  • BHE 0.19
  • MESO -0.27
  • Stochastic Oscillator
  • BHE 69.95
  • MESO 0.60

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: